Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

The conversation is about hair loss treatments, specifically discussing RU58841, with concerns about its safety and lack of research. Alternatives like finasteride, dutasteride, and minoxidil are mentioned, with some users sharing personal experiences and side effects.

A new hair growth spray in the UK contains finasteride 0.3%, minoxidil 5%, and tretinoin 0.01%, but some users find the finasteride concentration too high. Another brand offers a similar spray with a lower finasteride dose at a cheaper price, and some users report scalp irritation from the new spray.

Breezula, a potential new hair loss treatment, may receive FDA approval soon, but it is expected to be a weaker alternative to finasteride and minoxidil. Concerns include its twice-daily application and possible side effects like HPA axis suppression.

New hair loss treatments like stem cells, hair cloning, and gt20029 are unlikely to be available in the next 5-10 years, with some trials possibly starting by 2026. Current treatments like Minoxidil and Finasteride have been used for decades, and new developments depend on funding and successful trials.

CRISPR shows promise for treating hair loss by targeting specific genes. Current treatments include Minoxidil and finasteride, but CRISPR could offer a more precise solution, though it is still expensive and in early stages.

Finasteride may affect liver function and cortisol levels, potentially linking it to non-alcoholic fatty liver disease (NAFLD). More research is needed to understand this connection fully.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

The conversation discusses the mechanism of action of alfatradiol (17 alpha estradiol) in treating hair loss. It explores theories that it either inhibits 5 alpha reductase to prevent T->DHT conversion or aromatizes scalp T into 17-alpha-estradiol to save hair.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

The conversation discusses potential future hair loss treatments, including SCUBE3, hair follicle cloning, and GT20029, with mentions of past disappointments like CosmeRNA and hopes for treatments like Verteporfin for infinite donor hair.

The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

The conversation discusses hair loss treatments, specifically comparing rosemary and Redensyl, with the original poster already using finasteride and minoxidil. Users also mention using topical melatonin, caffeine, geranium, rosemary oil, jojoba, coconut, and argan oil for hair and scalp care.

The conversation discusses the potential of kintor pyrilutamide as a promising treatment for hair loss, with ongoing trials in various phases. There is skepticism due to delays in trial results, but the company is actively pursuing further trials.

Corticosterone inhibits GAS6, affecting hair follicle stem-cell activity, with potential implications for stress-related hair loss. Ashwagandha and Vitamin K are suggested for reducing cortisol, but their effectiveness is debated.

The conversation is about the availability of WINLEVI, a hair loss treatment, and the possibility of getting it compounded. The user is seeking information on when they can obtain the treatment.

Botox injections may be more effective than finasteride for hair growth by reducing scalp tension. The discussion also suggests choosing FUE over FUT due to potential loss of scalp elasticity with FUT.

PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.

A company is developing a topical dutasteride that targets hair follicles without significantly affecting systemic DHT levels, with trials underway to measure its effectiveness. Users discuss the potential benefits and skepticism around the formulation compared to existing treatments.

A user is attempting to reformulate a topical gel using PP-405 for hair loss, aiming to enhance its effectiveness with additional compounds. They discuss the potential of PP-405 compared to other treatments like Minoxidil and GT20029, and emphasize the importance of proper formulation for efficacy.

Finasteride and minoxidil remain the primary treatments for hair loss, with dutasteride being a more potent alternative. New treatments like VDPHL01 and topical antiandrogens are in development.

A 26-year-old shared their 5-year experience using finasteride and minoxidil for hair loss, noting initial improvements but later experiencing reduced libido and erection quality, leading them to switch from oral to topical finasteride. They advise starting with a low-dose topical solution and emphasize making informed decisions, acknowledging that while finasteride is effective, it can have side effects.

The user has been using Dutasteride and Minoxidil successfully for hair loss and is advised to double the doses post-transplant, but is skeptical about the necessity. Other users suggest maintaining the current dose and caution against potential side effects from increasing the dosage.

The conversation discusses a hair loss treatment regimen without finasteride, using oral and topical minoxidil, KX826, alfatradiol, and ketoconazole shampoo. Users debate the effectiveness and side effects of these treatments, with some suggesting alternatives like higher doses of minoxidil or RU58841.

PP405 aims to reactivate hair follicle stem cells to promote hair growth, but its effectiveness is debated. Some users are skeptical, citing past failures of similar treatments and questioning the company's claims.

Amplifica's AMP-303 showed a modest increase in hair growth, but results were inconsistent and potentially misleading. Hyaluronic acid and osteopontin are being explored for hair growth, with varying effects on different hair types and conditions.

A user started taking 0.5 mg dutasteride for hair loss, alongside topical minoxidil, and sought advice. Users shared experiences, noting potential hair shedding as a positive sign, and discussed side effects like libido changes, with some suggesting additional treatments like retinoids for better results.

A user was prescribed 10mg of oral minoxidil for hair loss, which they found too high, so they cut the pills to take 2.5mg daily. They are also using finasteride and are considering increasing the minoxidil dose to 5mg if needed.